ABOUT US
Offices
History
Pro Bono
Women's Networking Group
Awards
Community Involvement
SERVICES
Practice Areas
Industries
Experience
Related Services
ATTORNEYS
Attorney Search
DIVERSITY
Recruiting
Career Development
Workplace and Community
Women's Networking Group
Organizations
Events
NEWS & EVENTS
News Releases
Events
Webinars
In the News
Press Kit
Feature Articles
PUBLICATIONS
Newsletters
Articles
Subscribe
CAREERS
Law Students
Laterals
Paralegals and Administrative Staff
IN THIS PRACTICE
Attorneys
Events
In The News
News
Publications
Litigation
Overview
Alternative Dispute Resolution
Animal Law
Appellate Team
Avoidance Powers and Lender Liability
Civil and Criminal Antitrust Litigation
Class Action Litigation
Commercial Litigation
Consumer Product Safety Team
Employment Discrimination and Civil Rights Litigation
Energy Litigation
Environmental and Toxic Tort Litigation
Environmental Enforcement and Litigation
ERISA and Employee Benefits Litigation
Franchise and Distribution Litigation
Insurance Antitrust Litigation
Media and Communications Law
Patent Litigation
Product Liability
Real Estate Litigation
Reinsurance Litigation
Securities Litigation
Subprime Lending
Tax Litigation
Telecommunications Litigation
Trade Secrets Litigation
Trademark and Trade Dress Litigation
Trust and Estate Litigation
White Collar Crime and Corporate Compliance
In The News
February 1, 2012
'Fresh from the biotech pipeline ? 2011'
Nature Biotechnology
D. Christopher Ohly
This article about the U.S. FDA approval process for biosimilar drugs quotes Schiff Hardin partner Chris Ohly. Mr. Ohly, who focuses on pharmaceuticals in the firm's Intellectual Property Group, comments that companies moving through the biosimilar and interchangeable drug approval process may end up innovating their products as a result.
April 25, 2011
"Patents on the line"
BioCentury
D. Christopher Ohly
In this article about challenges in the Supreme Court to patent protections, Schiff Hardin partner Chris Ohly is quoted regarding the standards used to invalidate a patent.
February 11, 2011
"Patent reform looks likely to pass this year"
BioPharm Insight
D. Christopher Ohly
Schiff Hardin's Christopher Ohly, a partner in the firm's Intellectual Property group, is quoted in this pharmaceutical news service story on patent reform legislation. Mr. Ohly points out likely consequences of the legislation, including the significant change to first-to-file priority in patent applications.